Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Almaty, Kazakhstan, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oxus Acquisition Corp. (Nasdaq: OXUSU) (the “Company”) today announced that holders of the units sold in the Company’s initial public offering...
-
CARLSBAD, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- AppTech Corp. (“AppTech”) (OTC: APCX) a fintech company, announced today that the Company converted or cured the default on vast majority of its...
-
Dubai, UAE, Oct. 03, 2021 (GLOBE NEWSWIRE) -- (via Blockchain Wire) The long-awaited launch of the Bancambios DeFi project is here. The token, (ticker: BX), will be minted on top of the Solana...
-
BRITISH VIRGIN ISLANDS, Sept. 28, 2021 (GLOBE NEWSWIRE) -- (via Blockchain Wire) - Leading multi-chain, community-oriented launchpad, Starter (https://starter.xyz), today announced it will host the...
-
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pacifico Acquisition Corp. (NASDAQ: PAFOU, the "Company") announced today that an additional 750,000 units were issued pursuant to the underwriters'...
-
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development...
-
September 21, 2021 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of its Solana ETP (Ticker ASOL FP in Euro and ASOL NA in USD) and Polkadot...
-
London, UK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- (via Blockchain Wire) Oasis.app, a leading platform for decentralized finance, has integrated with the 1inch Network, a leading DEX aggregator, to...
-
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
-
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor...